Chen Xie1, Vinod Vijay Subhash1,2, Arpita Datta3, Natalia Liem1, Shi Hui Tan1,4, Mei Shi Yeo1, Woei Loon Tan1, Vivien Koh1, Fui Leng Yan1, Foong Ying Wong1, Wai Keong Wong5, Jimmy So6, Iain Beehuat Tan7, Nisha Padmanabhan8, Celestial T Yap3,9, Patrick Tan8, Liang Kee Goh4, Wei Peng Yong10,11. 1. Department of Haematology-Oncology, National University Hospital, Level 7, NUHS Tower Block, 1E, Kent Ridge Road, Singapore, 119228, Singapore. 2. Cancer Science Institute of Singapore, National University of Singapore, Singapore, Singapore. 3. Department of Physiology, National University of Singapore, Singapore, Singapore. 4. Centre for Quantitative Medicine, Duke-NUS Graduate Medical School, Singapore, Singapore. 5. Departments of Pathology and General Surgery, Singapore General Hospital, Singapore, Singapore. 6. Departments of Medicine, Surgery, and Pathology, National University Health System, Singapore, Singapore. 7. Department of Medical Oncology, National Cancer Centre Singapore, Singapore, Singapore. 8. Department of Cancer and Stem Cell Biology, Duke-NUS Graduate Medical School, Singapore, Singapore. 9. National University Cancer Institute, Singapore, Singapore. 10. Department of Haematology-Oncology, National University Hospital, Level 7, NUHS Tower Block, 1E, Kent Ridge Road, Singapore, 119228, Singapore. wei_peng_yong@nuhs.edu.sg. 11. Cancer Science Institute of Singapore, National University of Singapore, Singapore, Singapore. wei_peng_yong@nuhs.edu.sg.
Abstract
BACKGROUND: Melanoma-associated antigen (MAGE)-A3 is a member of the family of cancer-testis antigens and has been found to be epigenetically regulated and aberrantly expressed in various cancer types. It has also been found that MAGE-A3 expression may correlate with an aggressive clinical course and with chemo-resistance. The objectives of this study were to assess the relationship between MAGE-A3 promoter methylation and expression and (1) gastric cancer patient survival and (2) its functional consequences in gastric cancer-derived cells. METHODS: Samples from two independent gastric cancer cohorts (including matched non-malignant gastric samples) were included in this study. MAGE-A3 methylation and mRNA expression levels were determined by methylation-specific PCR (MSP) and quantitative real-time PCR (qPCR), respectively. MAGE-A3 expression was knocked down in MKN1 gastric cancer-derived cells using miRNAs. In addition, in vitro cell proliferation, colony formation, apoptosis, cell cycle, drug treatment, immunohistochemistry and Western blot assays were performed. RESULTS: Clinical analysis of 223 primary patient-derived samples (ntumor = 161, nnormal = 62) showed a significant inverse correlation between MAGE-A3 promoter methylation and expression in the cancer samples (R = -0.63, p = 5.99e-19). A lower MAGE-A3 methylation level was found to be associated with a worse patient survival (HR: 1.5, 95 % CI: 1.02-2.37, p = 0.04). In addition, we found that miRNA-mediated knockdown of MAGE-A3 expression in MKN1 cells caused a reduction in its proliferation and colony forming capacities, respectively. Under stress conditions MAGE-A3 was found to regulate the expression of Bax and p21. MAGE-A3 knock down also led to an increase in Puma and Noxa expression, thus contributing to an enhanced docetaxel sensitivity in the gastric cancer-derived cells. CONCLUSIONS: From our results we conclude that MAGE-A3 expression is regulated epigenetically by promoter methylation, and that its expression contributes to gastric cell proliferation and drug sensitivity. This study underscores the potential implications of MAGE-A3 as a therapeutic target and prognostic marker in gastric cancer patients.
BACKGROUND:Melanoma-associated antigen (MAGE)-A3 is a member of the family of cancer-testis antigens and has been found to be epigenetically regulated and aberrantly expressed in various cancer types. It has also been found that MAGE-A3 expression may correlate with an aggressive clinical course and with chemo-resistance. The objectives of this study were to assess the relationship between MAGE-A3 promoter methylation and expression and (1) gastric cancerpatient survival and (2) its functional consequences in gastric cancer-derived cells. METHODS: Samples from two independent gastric cancer cohorts (including matched non-malignant gastric samples) were included in this study. MAGE-A3 methylation and mRNA expression levels were determined by methylation-specific PCR (MSP) and quantitative real-time PCR (qPCR), respectively. MAGE-A3 expression was knocked down in MKN1 gastric cancer-derived cells using miRNAs. In addition, in vitro cell proliferation, colony formation, apoptosis, cell cycle, drug treatment, immunohistochemistry and Western blot assays were performed. RESULTS: Clinical analysis of 223 primary patient-derived samples (ntumor = 161, nnormal = 62) showed a significant inverse correlation between MAGE-A3 promoter methylation and expression in the cancer samples (R = -0.63, p = 5.99e-19). A lower MAGE-A3 methylation level was found to be associated with a worse patient survival (HR: 1.5, 95 % CI: 1.02-2.37, p = 0.04). In addition, we found that miRNA-mediated knockdown of MAGE-A3 expression in MKN1 cells caused a reduction in its proliferation and colony forming capacities, respectively. Under stress conditions MAGE-A3 was found to regulate the expression of Bax and p21. MAGE-A3 knock down also led to an increase in Puma and Noxa expression, thus contributing to an enhanced docetaxel sensitivity in the gastric cancer-derived cells. CONCLUSIONS: From our results we conclude that MAGE-A3 expression is regulated epigenetically by promoter methylation, and that its expression contributes to gastric cell proliferation and drug sensitivity. This study underscores the potential implications of MAGE-A3 as a therapeutic target and prognostic marker in gastric cancerpatients.
Authors: K Vazquez-Santillan; J Melendez-Zajgla; L Jimenez-Hernandez; G Martínez-Ruiz; V Maldonado Journal: Cell Oncol (Dordr) Date: 2015-08-29 Impact factor: 6.730
Authors: Martin Monte; Marta Simonatto; Leticia Y Peche; Debora R Bublik; Stefania Gobessi; Marco A Pierotti; Monica Rodolfo; Claudio Schneider Journal: Proc Natl Acad Sci U S A Date: 2006-07-17 Impact factor: 11.205
Authors: Rebecca R Florke Gee; Helen Chen; Anna K Lee; Christina A Daly; Benjamin A Wilander; Klementina Fon Tacer; Patrick Ryan Potts Journal: J Biol Chem Date: 2020-09-13 Impact factor: 5.157
Authors: Anthony P Conley; Wei-Lien Wang; John A Livingston; Vinod Ravi; Jen-Wei Tsai; Ali Ali; Davis R Ingram; Caitlin D Lowery; Christina L Roland; Neeta Somaiah; Patrick Hwu; Cassian Yee; Vivek Subbiah; Andrew Futreal; Alexander J Lazar; Shreyaskumar Patel; Jason Roszik Journal: Cancers (Basel) Date: 2019-05-15 Impact factor: 6.639
Authors: Aaron Chen; Alexis L Santana; Nicole Doudican; Nazanin Roudiani; Kristian Laursen; Jean-Philippe Therrien; James Lee; Diane Felsen; John A Carucci Journal: PLoS One Date: 2020-11-23 Impact factor: 3.240
Authors: Qi Wang; Pan Lu; Tao Wang; Qianqian Zheng; Yan Li; Sean X Leng; Xin Meng; Biao Wang; Jisheng Xie; Haiyan Zhang Journal: Cancer Med Date: 2020-03-30 Impact factor: 4.452